Edwards Lifesciences Stock Supported by TD Cowen Ahead of Q2 Earnings

Key Facts

Ahead of the second-quarter earnings release, Edwards Lifesciences stands out in the med-tech sector due to its robust financial performance in key growth segments. TD Cowen has reiterated its Buy rating for the stock with a $104 price target, supported by data showing total annual revenues of $6.0 billion. The firm expects the company to exceed its financial guidance, driven by strong momentum in transcatheter heart valve (THV) therapies, which now contribute approximately $4.0 billion to total revenue.

This optimism reflects the company's ability to achieve double-digit expansion in the THV segment while maintaining high operating margins, positioning it strongly against industry peers. According to market data, investors are weighing this performance against competitors like Medtronic, which has shown steady growth in cardiovascular segments. The $104 target represents a significant premium, as analysts link this valuation to continued dominance in the heart valve market and upcoming PROGRESS clinical trial results.

Regarding price action, EW closed at $85.00 (close July 20, 2026), trading within a daily range of $84.87 to $86.28. With no major healthcare events in the upcoming economic calendar, the actual earnings announcement remains the primary catalyst for traders to validate whether the THV segment's growth trajectory can sustain the current analyst valuation.